A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600E Mutations

S
Sandeep Batra, MD

Primary Investigator

Overview

This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations.

Description

Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, radiation therapy, and temozolomide may work better in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
  • Age: Between 3 Years - 25 Years
  • Gender: All

Inclusion Criteria

Patients must have eligibility confirmed by rapid central pathology and central molecular screening reviews performed on APEC14B1:

- Newly-diagnosed high-grade glioma such as anaplastic astrocytoma or glioblastoma

- Negative results for H3 K27M by immunohistochemistry (IHC)

- Negative results for BRAFV600E mutation by next-generation sequencing (NGS)

Patients must have histological verification of diagnosis. Patients with M+ disease (defined as evidence of neuraxis dissemination) are not eligible.

Patients with seizure disorder may be enrolled if seizures are well-controlled (i.e., patients must not have required rescue medications for uncontrolled seizures within 14 days prior to enrollment)

Patients must be enrolled and protocol therapy must be projected to begin no later than 31 days after definitive diagnostic surgery (Day 0)

Exclusion Criteria

Patients with the following histologies:

- Diffuse astrocytoma (grade 2)

- Oligodendrogliomas (any grade)

- Pleomorphic xanthoastrocytoma (PXA, any grade)

- Patients with primary tumor location of brainstem or spinal cord

- Patients with M+ disease (defined as neuraxis dissemination either by imaging or by cytology)

Patients must not have received any prior tumor-directed therapy including radiation therapy, chemotherapy (tumor-directed therapy), molecularly targeted agents, or immunotherapy for the treatment of HGG other than surgical intervention

Patients with gliomatosis cerebri type 1 or 2

Patients who are not able to receive protocol specified radiation therapy

Patients must not be currently receiving other anti-cancer agents

Patients with known constitutional mismatch repair deficiency syndrome (CMMR-D)/biallelic mismatch repair deficiency (bMMRD)

Female patients who are pregnant are ineligible due to risks of fetal and teratogenic adverse events as seen in animal/human studies

Lactating females are not eligible unless they have agreed not to breastfeed their infants

Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained

Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for 4 months after the last dose of veliparib

Updated on 09 Mar 2024. Study ID: 1811426979 (PHO-COG-ACNS1721)
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center